Literature DB >> 32396271

PPARα and NCOR/SMRT corepressor network in liver metabolic regulation.

Zhanfang Kang1, Rongrong Fan2.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARα, NR1C1) belongs to a large family of ligand-dependent nuclear receptors (NRs). It is one of the best studied NRs which controls the lipid metabolism (mainly fatty acid oxidation) and inflammation, and has been a promising target for treating metabolic disorders such as fatty liver and cardiometabolic diseases. The function of PPARα relies on its interaction with various coregulators upon different stimulating contexts, and, thereby, activates or represses its transcription targets in a gene-selective manner. Understanding the transcription factor and coregulator network underlying the PPARα regulation is prerequisite to decipher its gene- and context-selectivity for designing better therapeutic ligands. In this review, we will summarize current knowledge of PPARα coregulator network, with major focus on a relatively well-studied corepressor complex containing core subunits of nuclear receptor corepressor (NCOR or NCOR1), silencing mediator of retinoic acid and thyroid hormone receptor (SMRT or NCOR2), G-protein suppressor 2 (GPS2), transducin β-like protein 1 (TBL1 or TBL1X), TBL-related 1 (TBLR1 or TBL1XR1), and the catalytic core of histone deacetylase 3 (HDAC3). We will mainly review the molecular events of the complex and sub-complexes in controlling the liver metabolism. We will also discuss the potential perturbation of the subunit expression in human livers during liver metabolic disorder progression which potentially defines the patient disease susceptibility and drug responses.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  NCOR; PPAR; coregulators; liver metabolism; nuclear receptors

Year:  2020        PMID: 32396271     DOI: 10.1096/fj.202000055RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (HMGA2) and Nuclear Receptor Co-repressor 2 (NCOR2) in Osteoclastic Giant Cell-rich Tumors of Bone.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Marius Lund-Iversen; Ingvild Lobmaier; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

2.  Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation.

Authors:  Daisuke Aibara; Shogo Takahashi; Tomoki Yagai; Donghwan Kim; Chad N Brocker; Moshe Levi; Kimihiko Matsusue; Frank J Gonzalez
Journal:  iScience       Date:  2022-04-04

3.  Genetic mapping of metabolic traits in the blind Mexican cavefish reveals sex-dependent quantitative trait loci associated with cave adaptation.

Authors:  Misty R Riddle; Ariel Aspiras; Fleur Damen; Suzanne McGaugh; Julius A Tabin; Clifford J Tabin
Journal:  BMC Ecol Evol       Date:  2021-05-21

Review 4.  Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity.

Authors:  Kalina Duszka; András Gregor; Hervé Guillou; Jürgen König; Walter Wahli
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

5.  D-Mannose Regulates Hepatocyte Lipid Metabolism via PI3K/Akt/mTOR Signaling Pathway and Ameliorates Hepatic Steatosis in Alcoholic Liver Disease.

Authors:  Mengyao Hu; Yu Chen; Fan Deng; Bo Chang; Jialiang Luo; Lijun Dong; Xiao Lu; Yi Zhang; Zhengliang Chen; Jia Zhou
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

6.  Lgr5 + cell fate regulation by coordination of metabolic nuclear receptors during liver repair.

Authors:  Dan Qin; Shenghui Liu; Yuanyuan Lu; Yi Yan; Jing Zhang; Shiyao Cao; Mi Chen; Ning Chen; Wendong Huang; Liqiang Wang; Xiangmei Chen; Lisheng Zhang
Journal:  Theranostics       Date:  2022-08-15       Impact factor: 11.600

Review 7.  Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Anne Fougerat; Alexandra Montagner; Nicolas Loiseau; Hervé Guillou; Walter Wahli
Journal:  Cells       Date:  2020-07-08       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.